By Drug Target Review2024-05-15T12:00:21
The experimental therapy eliminated 90 percent of HSV-1 after facial infection and 97 percent of HSV-1 after genital infection.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2023-07-11T16:13:06
Sponsored by Agilent
2023-07-04T10:05:58
Sponsored by Revvity
2023-03-03T14:06:14
Sponsored by Bio-Techne
2024-01-26T13:22:42
Sponsored by bit.bio
2023-01-06T16:37:30
Sponsored by Catalent
Site powered by Webvision Cloud